Open Orphan was founded in 2017, with the goal of becoming Europe’s leading rare disease and orphan drug focused pharma services company by a management team with extensive industry and financial expertise. Open Orphan is listed on both the London and Dublin stock exchanges.
We are developing our European rare / orphan pharma services business by consolidating a number of smaller services companies in this highly fragmented but high margin sector. These companies are primarily operating in our initial core areas of regulatory, reimbursement, product launch and communications.We have developed a strong pipeline of potential acquisitions and are in advanced discussions with a large number of these. Post IPO, we aim to offer a complete platform of services in Europe primarily in the areas of regulatory approval, reimbursement, product launch and communications.
The orphan drug consulting space in Europe is highly fragmented and consists of many small players scattered across Europe. It is Open Orphan’s plan to acquire a number of these smaller players, consolidating them into the leading orphan drug consultancy services company in Europe.